Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus

EuroIntervention

Volumn 7, Issue SUPPL. K, 2011, Pages

  Ali, Rosli Mohd ^a   Degenhardt, Ralf ^b   Zambahari, Robaayah ^a   Tresukosol, Damras ^c   Ahmad, Wan Azman Wan ^d   Kamar, Haizal Bin Haron ^d   Kui Hian, Sim ^e   Ong, Tiong Kiam ^e   Ismail, Omar Bin ^f   Elis, Safari Bin ^f   Udychalerm, Wasan ^g   Ackermann, Hanns ^h   Boxberger, Michael ⁱ   Unverdorben, Martin ^b,j  

^a NATIONAL HEART INSTITUTE   (Malaysia)

^b Center for Cardiovascular Diseases   (Germany)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^e Sarawak Hospital   (Malaysia)

^f Penang Hospital   (Malaysia)

^g KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^h GOETHE UNIVERSITY   (Germany)

ⁱ Clinical Science   (Germany)

^j B Braun Medical Inc   (United States)

more..

Author keywords

Clinical outcome; Coronary; Diabetes mellitus; Drug eluting balloon; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CHROMIUM; CLOPIDOGREL; COBALT; INSULIN; ORAL ANTIDIABETIC AGENT; PACLITAXEL;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; BALLOON CATHETER; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART DEATH; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL TIME; THERAPY EFFECT; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CHROMIUM ALLOYS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES COMPLICATIONS; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALAYSIA; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; STENTS; THAILAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 80155154054     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV7SKA15     Document Type: Article

References (51)

1. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, Togni M, Billinger M, Tuller D, Seiler C, Roffi M, Corti R, Sutsch G, Maier W, Luscher T, Hess OM, Egger M, Meier B. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-662. (Pubitemid 41175673)
2. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HP. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. J Am Med Assoc. 2006;295:895-904.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323. (Pubitemid 37186209)
4. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel- eluting stent for de novo coronary lesions. Circulation. 2003;107: 38-42. (Pubitemid 36070930)
5. Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, Mehran R, Stone GW. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol. 2008;51:708-715. (Pubitemid 351227416)
6. Lasala JM, Cox DA, Lewis SJ, Tadros PN, Haas RC, Schweiger MJ, Chhabra A, Untereker WJ, Starzyk RM, Mascioli SR, Dawkins KD, Baim DS. Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention. 2009;5:67-77.
7. Airoldi F, Briguori C, Iakovou I, Stankovic G, Biondi-Zoccai G, Carlino M, Chieffo A, Montorfano M, Cosgrave J, Michev I, Rogacka R, Sangiorgi GM, Colombo A. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis. Am J Cardiol. 2006;97:1182-1187.
8. Berenguer A, Mainar V, Bordes P, Valencia J, Gomez S. [Efficacy of sirolimus-eluting stents in diabetics with complex coronary lesions]. Rev Esp Cardiol. 2006;59:117-124.
9. Jimenez-Navarro MF, Curiel E, Hernandez Garcia JM, Alonso Briales JH, Dominguez Franco A, Gomez Doblas JJ, De Teresa Galvan E. [Influence of diabetes mellitus on clinical outcome after percutaneous coronary revascularization]. Rev Esp Cardiol. 2002;55:365-371.
10. West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O'Neill WW, Mercado NF, Serruys PW. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation. 2004;109:867-873. (Pubitemid 38252739)
11. Bayerl DM, Siqueira E, Moscoso I, Santos E, Maeda A, Bittencourt O, Mauro MF, Cristovao S, Salman A, Sanches G, Mangione JA. Coronary stent implantation in diabetic versus non- diabetic patients. Early and late outcomes. Arq Bras Cardiol. 2000;75:365-368.
12. Kane GR, Patil CV, Sahoo PK, Bhatnagar D, Mathew R, Sethi RB. Coronary stenting in diabetics: six months clinical and angiographic outcome. Indian Heart J. 2000;52:416-420.
13. Zhang F, Dong L, Ge J. Meta-analysis of five randomized clini- cal trials comparing sirolimus- versus paclitaxel-eluting stents in patients with diabetes mellitus. Am J Cardiol. 2010;105:64-68.
14. Balducelli M, Ortolani P, Marzaroli P, Piovaccari G, Menozzi A, Manari A, Sangiorgio P, Tarantino F, Rossi R, Maresta A, Tondi S, Passerini F, Guastaroba P, Grilli R, Marzocchi A. Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: results of the Registro Regionale AngiopLastiche Emilia-Romagna Registry. Catheter Cardiovasc Interv. 2010;75:327-334.
15. Frobert O, Lagerqvist B, Carlsson J, Lindback J, Stenestrand U, James SK. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol. 2009;53:1660-1667.
16. Mahmud E, Ormiston JA, Turco MA, Popma JJ, Weissman NJ, O'Shaughnessy CD, Mann T, Hall JJ, McGarry TF, Cannon LA, Webster MW, Mandinov L, Baim DS. TAXUS Liberte attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. JACC Cardiovasc Interv. 2009;2:240-252.
17. Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug- eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol. 2009;103:345-349.
18. Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB. Clinical and angiographic outcomes in diabetics fromthe ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery dis- ease. JACC Cardiovasc Interv. 2009;2:967-976.
19. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, Wietze L, Sousa JE, Serruys PW, Morice MC. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial. Eur Heart J. 2004;25:107-112. (Pubitemid 38112148)
20. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005;353:663-670. (Pubitemid 41175674)
21. Chaves AJ, Sousa AG, Mattos LA, Abizaid A, Staico R, Feres F, Centemero M, Tanajura LF, Abizaid A, Pinto I, Maldonado G, Seixas A, Costa MA, Paes A, Mintz GS, Sousa JE. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial. Circulation. 2004;109: 861-866. (Pubitemid 38252738)
22. Mehilli J, Kastrati A, Schuhlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schomig A. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004;110:3627-3635. (Pubitemid 40003783)
23. Chen WH, Kaul U, Leung SK, Lau YK, Tan HC, Leung AW, Lee MK, Li SK, Ng W, Lee PY, Lam KF, Tse HF, Lau CP. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. J Invasive Cardiol.2005;17:534-538.
24. Saia F, Lemos PA, Hoye A, Sianos G, Arampatzis CA, de Feyter PJ, van der Giessen WJ, Smits PC, van Domburg RT, Serruys PW. Clinical outcomes for sirolimus-eluting stent implantation and vascular brachytherapy for the treatment of in-stent restenosis. Catheter Cardiovasc Interv. 2004;62:283-288. (Pubitemid 38868859)
25. Waksman R, Bhargava B, Mintz GS, Mehran R, Lansky AJ, Satler LF, Pichard AD, Kent KM, Leon MB. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J Am Coll Cardiol. 2000;36:65-68. (Pubitemid 30466113)
26. Waksman R, Bhargava B, Leon MB. Late thrombosis following intracoronary brachytherapy. Cathet Cardiovasc Intervent. 2000;49:344-347. (Pubitemid 30133532)
27. Waksman R, Ajani AE, White RL, Chan R, Bass B, Pichard AD, Satler LF, Kent KM, Torguson R, Deible R, Pinnow E, Lindsay J. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation. 2004;109:340-344. (Pubitemid 38133901)
28. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, Wong SC, Fish D, Ellis S, Holmes DR, Kerieakes D, Kuntz RE. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344:250-256. (Pubitemid 32108529)
29. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA, Guarneri EM, Steuterman S, Cloutier DA, Leon MB, Tripuraneni P. A subgroup analysis of the Scripps Coronary Radiation to Inhibit Proliferation Poststenting Trial. Int J Radiat Oncol Biol Phys. 1998;42:1097-1104. (Pubitemid 29004154)
30. Regar E, Serruys PW, Bode C, Holubarsch C, Guermonprez JL, Wijns W, Bartorelli A, Constantini C, Degertekin M, Tanabe K, Disco C, Wuelfert E, Morice MC. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002;106:1949-1956. (Pubitemid 35176300)
31. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, BÜhm M, Speck U. Randomized trial on the treatment of in-stent restenosis by a Paclitaxel-coated balloon catheter - PACCOCATH ISR I. Z Kardiol. 2005;94 (Suppl 1):V.
32. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, Leschke M, Ackermann H, Boxberger M, Speck U, Degenhardt R, Scheller B. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation. 2009;119:2986-2994.
33. Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M, Cremers B, Hardt S, Buerke M, Ackermann H, Boxberger M, Degenhardt R, Scheller B. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2010;99:165-174.
34. BBraun. International Coroflex Blue Register - Coroflex Blue "Real World" Register. 2006.
35. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-794.
36. Unverdorben M, Degenhardt R, Vallbracht C, Wiemer M, Horstkotte D, Schneider H, Nienaber C, Bocksch W, Gross M, Boxberger M. The paclitaxel-eluting Coroflextrade mark please stent pilot study (PECOPS I): Acute and 6-month clinical and angi- ographic follow-up. Catheter Cardiovasc Interv. 2006;67:703-710.
37. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, poly- mer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-1947. (Pubitemid 38544483)
38. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME. Clinical efficacy of polymer-based pacli- taxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306-3313. (Pubitemid 43739376)
39. Scheller B, Boxberger M, Calisse J, Kühler M, Nickenig G, Böhm M. Comparative study of a new CoCr coronary stent with a conventional bare stent in the porcine coronary model. submitted. 2006.
40. Grube E, Gerckens U, Muller R, Bullesfeld L. Drug eluting stents: initial experiences. Z Kardiol. 2002;91 Suppl 3:44-48. (Pubitemid 34809724)
41. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME. TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation. 2003;107:559-564. (Pubitemid 36176804)
42. Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C, Munzel T, Belardi J, Ruzyllo W, Bilodeau L, Kelbaek H, Ormiston J, Dawkins K, Roy L, Strauss BH, Disco C, Koglin J, Russell ME, Colombo A. Chronic Arterial Responses to Polymer- Controlled Paclitaxel-Eluting Stents: Comparison With Bare Metal Stents by Serial Intravascular Ultrasound Analyses: Data From the Randomized TAXUS-II Trial. Circulation. 2004;109: 196-200. (Pubitemid 38114139)
43. Kim JS, Lee BH, Ko YG, Choi D, Jang Y, Min PK, Yoon YW, Hong BK, Kwon HM, Ahn MS, Lee SH, Yoon JH, Lee BK, Kim BO, Kim BK, Oh SJ, Jeon DW, Yang JY, Cho JR, Jung JH, Ryu SK. Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: the Korean Multicenter Angioplasty Team (KOMATE) Registry. Catheter Cardiovasc Interv. 2008;72:601-607.
44. Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffre G, Prati F, Tamburino C, Ribichini F. Head-to-Head comparison of sirolimus- and paclitaxel- eluting stent in the same diabetic patient with multiple coronary artery lesions. A prospective, randomized, multicenter ctudy. Diabetes Care. 2008:15-19.
45. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ. A randomized comparison of sirolimus- versus Paclitaxel- eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol. 2008;52:727-733.
46. Feres F, Andrade PB, Costa RA, de Ribamar Costa J, Jr., Abizaid A, Staico R, Tanajura LF, Siqueira D, Maia JP, Lasave L, Sousa AG, Sousa JE. Angiographic and intravascular ultrasound findings following implantation of the Endeavor zotarolimus-eluting stents in patients from the real-world clinical practice. EuroIntervention. 2009;5:355-362.
47. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ. Everolimus-eluting versus paclitaxel- eluting stents in coronary artery disease. N Engl J Med. 2010;362: 1663-1674.
48. Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, Limbruno U. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010;96: 1291-1296.
49. Fanggiday JC, Stella PR, Guyomi SH, Doevendans PA. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: the DEBIUT (drug-eluting balloon in bifurcation Utrecht) registry. Catheter Cardiovasc Interv. 2008;71:629-635. (Pubitemid 351559549)
50. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med. 2006;355:2113-2124. (Pubitemid 44749319)
51. Mathey DG, Wendig I, Boxberger M, Bonaventurea K, Kleber FX. Treatment of bifurcation lesions with a drug-eluting balloon: the PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention 2011;7:K61-K65.